Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
Objective: clinical and economic analysis of including of secukinumab (SEC) in the essential drug list (EDL) and Federal Reimbursement (ONLS) to ensure the availability of the drug to patients with ankylosing spondylitis (AS) at the expense of health. Material and methods. A budget impact analysis w...
Saved in:
| Main Authors: | S. K. Zyryanov, I. N. Dyakov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01) -
Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis
by: R. O. Dreval
Published: (2021-02-01) -
THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01) -
Efficacy and safety of biologics for the treatment of ankylosing spondylitis: systematic literature review and network meta-analysis of treatments registered in the Russian Federation
by: T. V. Dubinina, et al.
Published: (2021-01-01) -
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01)